Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + pertussis + haemophilus influenzae type b + poliomyelitis vaccine + respiratory syncytial virus vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
This combination refers to the concomitant administration of a routine pediatric 5-in-1 vaccine (targeting diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b) and Sanofi's investigational live-attenuated respiratory syncytial virus (RSV) vaccine, SP0125. The RSV component, also known as RSV/ΔNS2/Δ1313/I1314L, was an intranasal candidate designed for infants and toddlers aged 6 to 24 months. This co-administration was evaluated in the Phase III CORAL study to ensure that the immune response to the routine pediatric vaccines was not compromised by the addition of the RSV vaccine. While the routine components (marketed as Pentacel) are widely approved, Sanofi discontinued the development of the SP0125 RSV vaccine candidate after it failed to meet efficacy endpoints in Phase III clinical trials.
- Brand names
- Pentacel
- Other names
- DTaP-IPV-Hib + RSV vaccinediphtheria + tetanus + pertussis + haemophilus influenzae type b + poliomyelitis vaccine-Sanofi Pasteur, a Sanofi Company-respiratory syncytial virus infection
02
Targets
Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)FIM2/FIM3 (Fimbriae types 2 and 3)PRP (Haemophilus influenzae type b polyribosylribitol phosphate capsular polysaccharide)PRN (Pertactin)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria + tetanus + pertussis + haemophilus influenzae type b + poliomyelitis vaccine + respiratory syncytial virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + pertussis + haemophilus influenzae type b + poliomyelitis vaccine + respiratory syncytial virus vaccine.